Results 81 to 90 of about 66,465 (188)
Eczema Herpeticum Kao Komplikacija Eritrodermijskog Pemphigus Foliaceus-A – Prikaz Slučaja
Sažetak Uvod. Eritrodermijski pemfigus foliaceus predstavlja autoimunsko bulozno oboljenje uzrokovano autoantitelima na proteine dezmozoma. Oštećenje epidermalne barijere i imunosupresija su faktori rizika za razvoj eczema herpeticum.
Jovana Pavlica +3 more
semanticscholar +1 more source
Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease that markedly impairs quality of life. Janus kinase inhibitors (upadacitinib, abrocitinib, and baricitinib) are effective therapies for moderate‐to‐severe AD but are associated with viral reactivation, particularly herpes zoster (HZ), due to immunosuppressive effects on interferon ...
Anna Mandecka +7 more
wiley +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Spyridon Gkalpakiotis +5 more
wiley +1 more source
Kaposi′s varicelliform eruption: A case series
Kaposi's varicelliform eruption is a rare and potentially fatal viral infection caused mainly by reactivation of herpes simplex virus. It concomitantly occurs with pre-existing skin conditions, mostly atopic dermatitis, so it is predominately found in ...
Bruno Ferrari +4 more
doaj +1 more source
Challenge in Diagnosis of Eczema Herpeticum in Rural Area in East Nusa Tenggara: a Case Report
Eczema herpeticum is an infection caused mostly by the herpes simplex virus which arises from an impaired skin barrier that may have a life-threatening bacterial complication. This case report unfolds the clinical reasoning behind diagnosing and treating
Nur Aida Oktasari +3 more
semanticscholar +1 more source
Background Janus kinase (JAK) inhibitors, as emerging drugs for the treatment of atopic dermatitis (AD), have demonstrated promising therapeutic potential. Objectives To evaluate the efficacy and safety of oral JAK inhibitors as monotherapy in moderate‐to‐severe AD.
XinWei Xie +6 more
wiley +1 more source
Aim This study aimed to compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in the treatment of atopic dermatitis (AD) using adverse events (AEs) reported to the Food and Drug Adverse Event Reporting System (FAERS).
Zijun Song +4 more
wiley +1 more source
Eczema herpeticum, Kapoși varicelliform eruption – case report [PDF]
Introducere Eczema herpeticum (EH) este o infecție virală care apare ca o complicație la pacienții cu dermatită atopică (DA). Mai frecvent sunt afectați sugarii și copiii.
Gogu, Vladislav +6 more
core +1 more source
Dermatopathologic emergencies part ii: Dermatopathologic and situational
In dermatopathology, there are several conditions which must be addressed emergently. While some conditions necessitate emergent intervention because of the pathology of the cutaneous manifestations, others require recognition of the underlying serious ...
Douglas H Atmatzidis +3 more
doaj +1 more source
Background Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods This prospective study
Zheng Li +12 more
wiley +1 more source

